Coronavirus Disease: New Humans Challenge and Known Approaches to Treatment
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Andreani J, Le Bideau M, Duflot I. In vitro testing of Hydroxychloroquine and Azithromycin on SARS-CoV-2 shows synergistic effect. https://www.mediterranee-infection.com/wp-content/uploads/2020/03/La-Scola-et-al-V1.pdf. 2020. [Preprint].
Andrew A. Lover. Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial. medRxiv 2020.03.22.20040949. 2020 [Preprint]
Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1cells/ Banjanac M, Munić Kos V., Nujić K. et al // Pharmacol Res. 2012 Oct;66(4):357-62. doi: 10.1016/j.phrs.2012.06.011. Epub 2012 Jul 3.
Azithromycin augments rhinovirusinduced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation / Menzel M., Akbarshahi H., Tufvesson E. et al. Oncotarget.- 2017, May 9;8(19):31601-31611. doi: 10.18632/oncotarget.16364.
Azithromycin Binding to the SARSCoV-2 Spike (S)Protein – ACE2 Complex. ChemRxiv. https://doi.org/10.26434/chemrxiv.12015792.v2. 2020. [Preprint].
Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind-placebo-controlled trial. / Brusselle GG, Vanderstichele C, Jordens P, et al. // Thorax. 2013;68:322–9. doi: 10.1136/thoraxjnl-2012-202698.
Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients // Menzel M., Akbarshahi H., Bjermer L. et al., Sci Rep. 2016. – 6: 28698. Published online 2016 Jun 28. doi: 10.1038/srep28698
Azithromycin can prolong QT interval and suppress ventricular contraction, but will not induce torsade de pointes / Ohara H, Nakamura Y, Watanabe Y. et al.// Cardiovasc Toxicol. 2015;15(3):232-40.
Blood, Tissue, and Intracellular Concentrations of Azithromycin during and after End of Therapy / Matzneller P., Krasniqi S., Kinzig M. et al.// Antimicrobial Agents and Chemotherapy p. 1736–1742 April 2013 Vol. 57, N 4.
Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Drug Saf. 2018;41(10):919-931.
Cardiovascular complications of severe acute respiratory syndrome / Yu C.M., Wong R.S., Wu E.B. et al.// Postgrad Med J 2006;82(964):140-4.
Choi Y, Lim HS, Chung D, Choi JG, Yoon D. Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice. Biomed Res Int. 2018;2018:1574806.
Chico RM, Chandramohan D. Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. Expert Opin Drug Metab Toxicol. 2011;7(9):1153-67.
Clinical and antimicrobial effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day followup : an observational study. / Gautret P., Lagier J.C., Parola P. et al.// Travel Med Infect Dis. 2020AprAA:101663
Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. World Health Organization. Available at https://www.who.int/publications-detail/clinicalmanagement-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(ncov)-infection-is-suspected. 2020 Mar 13
Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, Marseille, France. / Million M, Lagier JC, Gautret P, et al. // https://www.mediterranee-infection.com/wp-content/uploads/2020/04/MS.pdf 2020 [Preprint]
Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults. / Sagara I, Oduro AR, Mulenga M. et al. // Malar J. 2014;13:458.
Giudicessi J, Ackerman M. Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused ? Cleve Clin J Med. 2013;80(9):539-44.
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial / Gauret P., Lagier J.S., Parola P. et al.// Int J Antimicrob Agents. 2020 Mar 20:105949. doi: 10.1016/j.ijantimicag.2020.105949. [Epub ahead of print]
Hydroxychloroquine-Azithromycin and COVID-19/ Gautret P., Lagier J.S., Parola P. et al. // Available at https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf. 2020 Mar 30.
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 // Adarsh Bhimraj, Rebecca L. Morgan, Shumaker A.H. et al., Published by IDSA, 4/11/2020.
Ming Zhao. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies // Int J Antimicrob Agents.- 2020 Apr 16: 105982 doi: 10.1016/j.ijantimicag.2020.105982 [Epub ahead of print]
New treatment regimes for virus-induced exacerbations of asthma / Edwards MR, Kebadze T, Johnson MW et al. // Pulm Pharmacol Ther. 2006;19:320–34.
Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells / Schogler A., Korpf B.S., Edwards M.R. et al.// Eur Respir J 2015; 45: 428–439.
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 // Barlow A.; Landolf K.M.; Barlow B. et al., Pharmacotherapy. 2020; (ISSN: 1875-9114)
Rothan H.A., Byrareddy S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak// J Autoimmun. 2020, 109: 102433. doi: 10.1016/j.jaut.2020.102433. Epub 2020 Feb 26.
Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use of COVID-19: a multinational, network cohort and self-controlled series study / Lane J, Weaver J, Kostka K. et al. // medRxiv 2020.04.08.20054551. 2020 [Preprint]
Simpson TF, Kovacs RJ, Stecker EC. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19. American College of Cardiology; Cardiology Magazine. Available at https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquineazithromycin-treatment-for-covid-19. 2020 Mar 29.
The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future / Jin-Yan Li, Zhi You, Qiong Wang at al. // Microbes Infect .- 2020, Mar 22(2).- p. 80-85.
The Immunomodulatory Effects of Macrolides A Systematic Review of the Underlying Mechanisms/ Zimmermann P., Ziesenitz V.C., Curtis N., Ritz N. // Front. Immunol., 13 March 2018 | https://doi.org/10.3389/fimmu.2018.00302
The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin / Chorin E, Dai M, Shulman E. et al. // medRxiv 2020.04.02.20047050. 2020 [Preprint]
Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020mar18. pii:ehaa231.
Yu Chen, Quanium Liu, Deyin Guo. Emerging coronaviruses: Genome structure, replication, and pathogenesis // J Med Virol. 2020 Apr; 92(4): 418–423. Published online 2020 Feb 7. doi: 10.1002/jmv.25681
